A randomized, placebo-controlled, double blind, multiple ascending dose, phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of QRL-101 in healthy participants

2024-513127-16-00 Protocol QRL-101-03 Human pharmacology (Phase I) - Other Ended

Start 24 Jun 2024 · End 14 Jan 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol QRL-101-03

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 60
Countries 1
Sites 1

NA - healthy volunteers

Key facts

Sponsor
Quralis Corp.
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Trial duration
24 Jun 2024 → 14 Jan 2025
Decision date (initial)
2024-06-20
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

NA - healthy volunteers

VersionLevelCodeTermSystem organ class
21.1 PT 10002026 Amyotrophic lateral sclerosis 100000004852

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Quralis Corp.

Sponsor organisation
Quralis Corp.
Address
100 Cambridge Park Drive
City
Cambridge
Postcode
02140-2369
Country
United States

Scientific contact point

Organisation
Quralis Corp.
Contact name
Thomas Bowman, MD

Public contact point

Organisation
Quralis Corp.
Contact name
Principal Investigator

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 60 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-06-24 2025-01-14 2024-06-24 2025-01-14

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-13 Netherlands Acceptable
2024-06-20
2024-06-20
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-10-21 Netherlands Acceptable
2024-06-20
2024-10-21
3 NON SUBSTANTIAL MODIFICATION NSM-2 2025-01-13 Netherlands Acceptable
2024-06-20
2025-01-13